A strain of Lactobacillus rhamnosus VB336 producing lipase inhibitor and its application and culture device

By developing Lactobacillus rhamnosus VB336, this strain can secrete lipase inhibitors and inhibit pathogens, solving the problem of major side effects of existing weight loss drugs and achieving safe and effective weight loss and intestinal microbiota regulation effects.

CN118374419BActive Publication Date: 2024-11-22HANGZHOU VICROBX BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410825955.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-22
Estimated Expiration
2044-06-25

AI Technical Summary

Technical Problem

Existing weight loss drugs mostly act on the central nervous system, have strong side effects, and lack safe and effective lipase inhibitors to improve weight loss effects.

Method used

A strain called Lactobacillus rhamnosus VB336 was developed. This strain can secrete lipase inhibitors, inhibit the hydrolytic activity of fat, making excess fat unable to be absorbed in the intestine, and at the same time has the ability to inhibit pathogens, which is used to regulate the intestine. Fungus.

Benefits of technology

Weight loss effect and intestinal flora regulation are achieved, the disease risk caused by pathogenic infection is reduced, and a safe and effective weight loss plan is provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118374419B_ABST
    Figure CN118374419B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of microorganisms. The present invention proposes a strain of Lactobacillus rhamnosus VB336 producing a lipase inhibitor and its application and culture device. The Lactobacillus rhamnosus VB336 was deposited in the China Center for Type Culture Collection on March 8, 2024, with a deposit number of CCTCC M 2024432. The Lactobacillus rhamnosus VB336 of the present invention has a strong ability to inhibit lipase activity and inhibit common pathogens, and is resistant to gastric acid and bile salts, has strong stability in intestinal fluid, and can be used to inhibit fat hydrolysis and / or lose weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of microorganisms, and in particular to a strain of Lactobacillus rhamnosus VB336 producing a lipase inhibitor and an application and a culture device thereof. Background Art

[0002] There are many kinds of microorganisms in the human intestine, and their number is huge, forming a complex ecosystem in the intestine, which is closely related to human health. Lactobacillus is an important probiotic in the human intestine, which plays a vital role in maintaining the microecological balance of the host intestine and improving the function of the immune system.

[0003] Studying the causes of obesity and developing safe and effective weight loss drugs have become research areas of worldwide concern. Many weight loss drugs that have been developed and applied so far act on the central nervous system and have strong side effects, such as causing central nervous system excitement (including insomnia, tension, anxiety, nightmares, irritability, etc.), blood pressure rise or fall, and heart valve disease. Pancreatic lipase inhibitors are a relatively safe new type of weight loss drug. They selectively inhibit the hydrolysis activity of lipase, so that excess fat cannot be hydrolyzed into small molecule hydrolyzates in the intestines, and is not absorbed and stored by the human body, while having no effect on the absorption of other nutrients, thereby achieving a weight loss effect. Therefore, the development of suitable lipase inhibitors can greatly improve the pessimistic status quo of the weight loss drug market. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0005] To this end, in a first aspect of the present invention, the present invention provides a Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) VB336. According to an embodiment of the present invention, the Lactobacillus rhamnosus VB336 was deposited in the China Center for Type Culture Collection on March 8, 2024, with the deposit number of CCTCC M 2024432.

[0006] The Lactobacillus rhamnosus VB336 screened by the present invention can secrete a lipase inhibitor, and the hydrolysis activity of lipase on fat is reduced or inhibited, so that excess fat cannot be hydrolyzed into small molecules that can be absorbed by the body in the intestine, thereby achieving the effect of weight loss; in addition, the bacteria can inhibit common pathogens and can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0007] In a second aspect of the present invention, the present invention provides a fermentation broth. According to an embodiment of the present invention, the fermentation broth is fermented by the Lactobacillus rhamnosus VB336 described in the first aspect. The fermentation broth of the present invention can be used to inhibit fat hydrolysis and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0008] In the third aspect of the present invention, the present invention provides a bacterial suspension. According to an embodiment of the present invention, the bacterial suspension includes the Lactobacillus rhamnosus VB336 described in the first aspect. The bacterial suspension of the present invention can be used to inhibit fat hydrolysis and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0009] In the fourth aspect of the present invention, the present invention proposes the use of the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation liquid described in the second aspect, or the bacterial suspension described in the third aspect in the preparation of medicines, health products, or feeds for inhibiting lipase activity and / or reducing weight. The health products and feeds of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora, and the medicines of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora.

[0010] In the fifth aspect of the present invention, the present invention proposes the use of the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation liquid described in the second aspect, or the bacterial suspension described in the third aspect in the preparation of medicines or feeds that inhibit the activity of pathogenic bacteria. The feed of the present invention can be used to regulate intestinal flora, and the medicine of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0011] In the sixth aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition comprises at least one of the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect. The composition of the present invention can be used to inhibit lipase activity and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0012] In the seventh aspect of the present invention, the present invention provides a method for inhibiting lipase activity in vitro. According to an embodiment of the present invention, the method comprises: mixing at least one of the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect with the lipase. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit the activity of lipase.

[0013] In the eighth aspect of the present invention, the present invention proposes a method for weight loss. According to an embodiment of the present invention, the method comprises: administering the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation broth described in the second aspect, or the bacterial suspension described in the third aspect to a subject. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit the activity of lipase, so that excess fat cannot be hydrolyzed into small molecules that can be absorbed by the body in the intestine, thereby achieving the effect of weight loss.

[0014] In the ninth aspect of the present invention, the present invention provides a method for inhibiting the growth of pathogens in vitro. According to an embodiment of the present invention, the method comprises: co-culturing the pathogens with at least one of the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit the growth of pathogens.

[0015] In the tenth aspect of the present invention, the present invention provides a culture device or production device for the Lactobacillus rhamnosus VB336 described in the first aspect, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the sixth aspect. The culture device or production device according to the embodiment of the present invention can mass-produce the Lactobacillus rhamnosus VB336, fermentation broth, bacterial suspension or composition described in the present invention.

[0016] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0018] Figure 1 This is a scanning electron microscopy result diagram of Lactobacillus rhamnosus VB336 according to Example 2 of the present invention;

[0019] Figure 2 This is a graph showing the test results of the choline tolerance of Lactobacillus rhamnosus VB336 according to Example 4 of the present invention;

[0020] Figure 3 This is a graph showing the test results of the artificial simulated gastric juice tolerance of Lactobacillus rhamnosus VB336 according to Example 4 of the present invention;

[0021] Figure 4This is a graph showing the test results of the tolerance of Lactobacillus rhamnosus VB336 to artificial simulated intestinal fluid according to Example 4 of the present invention. DETAILED DESCRIPTION

[0022] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.

[0023] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In the description of the present invention, the meaning of "plurality" and "multiple" is at least two or two, such as two, two, three, three, etc., unless otherwise clearly and specifically defined.

[0024] In this document, the terms “include”, “have” or “comprises” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.

[0025] As used herein, the term "optionally" generally means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0026] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0027] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0028] As used herein, the terms "treatment" and "alleviation" both refer to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, especially humans, including: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a strain, fermentation broth, bacterial suspension or composition to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a strain, fermentation broth, bacterial suspension or composition described herein to an individual in need.

[0029] As used herein, the term "carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is contemplated.

[0030] strain

[0031] In some embodiments, the present invention proposes a Lactobacillus rhamnosus VB336, which was deposited in the China Center for Type Culture Collection on March 8, 2024, with a deposit number of CCTCC M 2024432.

[0032] According to some specific embodiments of the present invention, the above-mentioned Lactobacillus rhamnosus VB336 may further include at least one of the following additional technical features:

[0033] According to some specific embodiments of the present invention, the Lactobacillus rhamnosus VB336 has a 16S rRNA sequence as shown in SEQ ID NO:1.

[0034] The new strain of Lactobacillus rhamnosus VB336 screened by the present invention can secrete a lipase inhibitor, and the hydrolysis activity of lipase on fat is reduced or inhibited, so that excess fat cannot be hydrolyzed into small molecules that can be absorbed by the body in the intestine, thereby achieving the effect of weight loss; in addition, the bacterium can inhibit common pathogens, can be used to regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection, and has high application value.

[0035] In this document, the term "Lactobacillus rhamnosus" (Lacticaseibacillus rhamnosus) VB336", "Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus)VB336", "Lactobacillus rhamnosus VB336", "Lactobacillus rhamnosus VB336", "VB336 strain" and "VB336" are synonymous.

[0036] Lipase (Lipase, glycerol ester hydrolase) belongs to the carboxyl ester hydrolase class and can gradually hydrolyze triglycerides into glycerol and fatty acids. In addition, lipase has a variety of catalytic abilities, for example, it can catalyze the hydrolysis, alcoholysis, esterification, transesterification and reverse synthesis of triacylglycerol and other water-insoluble esters, and also show the activities of some other enzymes, such as phospholipase, lysophospholipase, cholesterol esterase, acyl peptide hydrolase activity, etc. The different activities of lipase depend on the characteristics of the reaction system, such as promoting ester hydrolysis at the oil-water interface, and enzymatic synthesis and ester exchange in the organic phase. In this article, Lactobacillus rhamnosus VB336 can produce a lipase inhibitor that inhibits lipase activity, and the lipase activity includes but is not limited to the hydrolysis activity of lipase. The lipase described herein includes any natural or synthetic lipase, for example, animal lipase, plant lipase and microbial lipase.

[0037] Fermentation Broth

[0038] In some embodiments, the present invention provides a fermentation broth, which is fermented by the aforementioned Lactobacillus rhamnosus VB336. The fermentation broth of the present invention can be used to inhibit fat hydrolysis and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0039] It should be noted that the "fermentation broth" of the present invention refers to the solution obtained after culturing Lactobacillus rhamnosus VB336 for a period of time, which solution mainly contains Lactobacillus rhamnosus VB336 and its metabolites; or the supernatant after further treatment by centrifugation, filtration and other means, which supernatant mainly contains the metabolites of Lactobacillus rhamnosus VB336.

[0040] bacterial suspension

[0041] In some embodiments, the present invention provides a bacterial suspension, which includes the aforementioned Lactobacillus rhamnosus VB336. The bacterial suspension of the present invention can be used to inhibit fat hydrolysis and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0042] It should be noted that the bacterial suspension can be obtained by treating the above fermentation broth by means of centrifugation, resuspension, etc.

[0043] use

[0044] In some embodiments, the present invention proposes the use of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth or bacterial suspension in the preparation of medicines, health products or feeds for inhibiting lipase activity and / or reducing weight. The health products and feeds of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora, and the medicines of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora.

[0045] In some embodiments, the present invention provides the use of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth or bacterial suspension in the preparation of medicines or feeds that inhibit the activity of pathogenic bacteria. The feed of the present invention can be used to regulate intestinal flora, and the medicine of the present invention can be used to regulate intestinal flora, prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0046] According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:

[0047] According to an embodiment of the present invention, the pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Listeria, Shigella, Enterococcus faecalis, Clostridium perfringens, Malassezia, Candida albicans, Porphyromonas gingivalis and Streptococcus mutans.

[0048] Medicines, health products or feed

[0049] The present invention provides a medicine, health product or feed, which includes at least one of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth or bacterial suspension. The health product or feed of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora. The medicine of the present invention can be used to inhibit lipase activity and / or reduce weight, and regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0050] According to an embodiment of the present invention, the above-mentioned medicine, health product or feed may further include at least one of the following additional technical features:

[0051] According to an embodiment of the present invention, it further comprises pharmaceutically acceptable excipients or carriers, excipients or carriers acceptable in food or health products, or excipients or carriers acceptable in animal feed.

[0052] As used herein, "acceptable in food" refers to substances or compositions that can be consumed by humans, which may be adjusted according to the food requirements of different countries.

[0053] As used herein, "acceptable in health products" refers to substances or compositions that can be consumed by humans, which may be adjusted according to the health product requirements of different countries.

[0054] In this article, "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, "pharmaceutically acceptable" as described in the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.

[0055] In this context, "adjuvant or carrier acceptable in animal feed" refers to a substance or composition that can be consumed by animals, which may be adjusted according to the animal feed requirements of different countries.

[0056] As used herein, the term "pharmaceutically acceptable carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is covered.

[0057] In this article, the term "pharmaceutically acceptable excipient" may include any solvent suitable for a specific target dosage form. Except for any conventional excipients that are incompatible with the Lactobacillus rhamnosus VB336 disclosed in the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present disclosure.

[0058] According to an embodiment of the present invention, at least one of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth and bacterial suspension is added or inoculated into feed, or added to medicine, thereby further obtaining feed having the function of inhibiting lipase activity and / or reducing weight, and regulating the function of intestinal flora, or obtaining medicines that can inhibit lipase activity and / or reduce weight, and regulate the function of intestinal flora, prevent, alleviate and / or treat pathogenic bacteria infection or diseases caused by pathogenic bacteria infection.

[0059] Exemplarily, the aforementioned foods include but are not limited to: probiotic tablets, fermented dairy products (such as probiotic yogurt), probiotic solid beverages, probiotic milk powder, probiotic cheese, probiotic soy products, probiotic candies, probiotic fermented vegetables, etc.

[0060] For example, the aforementioned medicines include but are not limited to: medicines for human use and medicines for animals. The aforementioned medicines for animals may be for pets, livestock, or wild animals.

[0061] Illustratively, the aforementioned health care products include but are not limited to: health care products for humans and health care products for animals.

[0062] It should be noted that the characteristics and advantages described above for Lactobacillus rhamnosus VB336 are also applicable to the medicine, health product or feed and will not be repeated here.

[0063] Composition

[0064] In some embodiments, the present invention provides a composition comprising at least one of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth and bacterial suspension. The composition of the present invention can be used to inhibit lipase activity and / or reduce weight, regulate intestinal flora, and prevent, alleviate and / or treat diseases caused by pathogenic bacteria infection.

[0065] According to an embodiment of the present invention, the above composition may further include at least one of the following additional technical features:

[0066] According to an embodiment of the present invention, the composition further comprises an ingestible excipient and / or carrier.

[0067] According to an embodiment of the present invention, the excipient includes at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent and a sustained-release agent.

[0068] According to an embodiment of the present invention, the carrier includes at least one selected from sugars, cellulose and its derivatives, calcium phosphates, alkaline earth metal stearates, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

[0069] According to an embodiment of the present invention, the dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

[0070] method

[0071] In some embodiments, the present invention provides a method for inhibiting lipase activity in vitro, the method comprising: co-culturing the aforementioned Lactobacillus rhamnosus VB336, at least one of the fermentation broth and the bacterial suspension with lipase. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit lipase activity, so that excess fat cannot be hydrolyzed into small molecules that can be absorbed by the body, and the method can be used for non-diagnostic and / or non-therapeutic purposes, such as for scientific research.

[0072] In some embodiments, the present invention provides a method for weight loss, comprising: administering to a subject at least one of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth, and bacterial suspension. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit the activity of lipase, so that excess fat cannot be hydrolyzed into small molecules that can be absorbed by the body in the intestine, thereby achieving the effect of weight loss.

[0073] In some embodiments, the present invention provides a method for inhibiting the growth of pathogenic bacteria in vitro, the method comprising: co-culturing the pathogenic bacteria with at least one of the aforementioned Lactobacillus rhamnosus VB336, fermentation broth and bacterial suspension. As mentioned above, the Lactobacillus rhamnosus VB336 of the present invention can effectively inhibit the growth of pathogenic bacteria.

[0074] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:

[0075] According to an embodiment of the present invention, the pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Listeria, Shigella, Enterococcus faecalis, Clostridium perfringens, Malassezia, Candida albicans, Porphyromonas gingivalis and Streptococcus mutans.

[0076] Device

[0077] In some embodiments, the present invention provides a culture device or production device for the aforementioned Lactobacillus rhamnosus VB336, fermentation broth, bacterial suspension or composition. The culture device or production device according to the embodiment of the present invention can realize mass production of the Lactobacillus rhamnosus VB336, fermentation broth, bacterial suspension or composition described in the present invention.

[0078] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0079] Example 1 Isolation and identification of strains

[0080] Samples from different sources were collected, including 20 fresh feces from healthy infants and 20 fresh feces from healthy adults. 0.5 g of feces was added to a 15 mL sterile collection tube containing 5 mL of PBS solution and oscillated to mix. Then, 1 mL of the solution was taken for gradient dilution to prepare different gradients of diluted bacterial suspension. 100 μL of each diluted bacterial suspension was spread on an MRS agar plate and cultured anaerobically at 37 ° C for 48 h. After the culture, colonies with different morphologies were picked for streaking, purification and DNA extraction. 16S rRNA was sequenced after PCR amplification with specific primers, and glycerol tubes were stored for the corresponding strains. According to the results of 16S rRNA identification, 148 strains of Lactobacillus were selected and numbered A01-A148. Among them, there were 10 strains of Lactobacillus casei, 24 strains of Lactobacillus paracasei, 32 strains of Lactobacillus rhamnosus, 49 strains of Lactobacillus plantarum, 8 strains of Lactobacillus fermentum, 9 strains of Lactobacillus reuteri, and 16 strains of Lactobacillus acidophilus.

[0081] Example 2 Strain Screening

[0082] 1.1 Preparation of lipase

[0083] (1) Prepare 0.02 mol / L anhydrous disodium hydrogen phosphate buffer solution (pH = 9.3);

[0084] (2) Prepare 8% lipase solution with the above-mentioned anhydrous disodium hydrogen phosphate buffer, dissolve it in a grinding tube, grind it at 60 Hz for 2 minutes at 4°C, centrifuge it to obtain the supernatant, adjust the pH to 8.0 with NaOH solution, and store it in a refrigerator at -80°C;

[0085] (3) Dilute the above 8% lipase solution to 1% concentration with 0.02 mol / L disodium hydrogen phosphate (pH = 10.3) and set aside.

[0086] 2.2 Preparation of fat emulsion

[0087] (1) Preparation of 100 mmol / L tris-HCl buffer (pH = 8.0): weigh 1.21 g of tris reagent and dissolve it in 100 mL of sterile water. After dissolution, adjust the pH to 8.0 with dilute hydrochloric acid.

[0088] (2) Take 0.3 mL of the emulsion stock solution, add 29.7 mL of the above 100 mmol / L tris-HCl buffer (pH=8.0), mix well, and obtain a 100-fold diluted emulsion. Mix the 100-fold diluted emulsion and 100 mmol / L tris-HCl buffer (pH=8.0) in a 1:1 ratio to obtain a 200-fold diluted emulsion.

[0089] 2.3 Preparation of orlistat at different concentrations

[0090] (1) Preparation of 100 μg / mL orlistat stock solution: Weigh 4 mg of orlistat standard and dissolve it in 40 mL of sodium hydrogen phosphate solution, pH = 10.3, and sonicate until completely dissolved.

[0091] (2) Use 0.02 mol / L disodium hydrogen phosphate buffer (pH = 10.3) to gradually dilute the 100 μg / mL orlistat stock solution to 50 μg / mL, 25 μg / mL, 10 μg / mL, 8 μg / mL, 5 μg / mL, 2.5 μg / mL, and 1 μg / mL.

[0092] The sources of the experimental reagents used in this example are shown in Table 1.

[0093] Table 1. Experimental materials

[0094]

[0095] 2.4 Lipase inhibition experiment of orlistat

[0096] (1) Orlistat and lipase inhibition experiments were performed using 96-well plates and divided into three groups;

[0097] ①Blank control group: 180 μL of 200-fold diluted emulsion + 10 μL of pH=8.0 tris-HCl buffer + 10 μL of pH=10.3 disodium hydrogen phosphate buffer;

[0098] ② Negative control group with enzyme: 180 μL of 200-fold diluted emulsion + 10 μL of 1% lipase solution + 10 μL of pH=10.3 disodium hydrogen phosphate buffer;

[0099] ③ Orlistat positive control group: 180 μL of 200-fold diluted emulsion + 10 μL of 1% lipase solution + 10 μL of orlistat standard solution of different concentrations;

[0100] In a 96-well plate, the respective reagent solutions were added according to the above groups. In group ③, the enzyme solution and orlistat solution were added first and reacted for 15 minutes before the emulsion was added. The emulsions of each group were added at the same time point to ensure that the enzyme reaction time was the same. The OD value of the emulsion was detected by an ELISA instrument at 490nm at 0h, 45 minutes, and 2h of reaction, and the hydrolysis effect of the enzyme on the emulsion was calculated by the change of the OD value of the emulsion.

[0101] (2) Calculation method of lipase hydrolysis rate and orlistat lipase inhibition rate:

[0102] Lipase hydrolysis rate % = (blank control group OD-enzyme solution negative control group OD) / blank control group OD * 100%

[0103] The inhibition rate of orlistat on lipase (%) = (hydrolysis rate of enzyme solution negative control group - hydrolysis rate of orlistat positive control group) / hydrolysis rate of enzyme solution negative control group * 100%.

[0104] 2.5 Screening of lipase inhibitor strains

[0105] (1) MRS finished medium: Weigh 54 g of the finished medium, add 1 L of pure water, stir to dissolve, and then divide into shake flasks. Sterilize at 121℃ for 15 min.

[0106] (2) Strain culture

[0107] ① Bacterial source: glycerol tubes of the different strains described in Example 1 stored at -80°C.

[0108] ② Strain inoculation method: Use a glycerol tube directly connected to liquid culture medium for bacterial culture, and the inoculation amount ranges from 0.2 to 1%.

[0109] ③Liquid culture method: According to the growth characteristics of the strain, place it in an anaerobic workstation and culture it at 37℃ for 18 to 24 hours.

[0110] (3) Sample preparation

[0111] When testing lipase inhibitors, samples are divided into supernatant and whole fluid according to different processing methods:

[0112] Supernatant: Take 0.5 mL of the above bacterial solution, centrifuge at 14,000 rpm for 10 minutes, and take the supernatant for inspection;

[0113] Whole liquid: Take 0.5 mL of the above bacterial liquid, add it to a grinding tube, grind it at 4°C and 60 Hz for 2 minutes each time, grind it 8 times in total, centrifuge it at 14,000 rpm for 10 minutes, and take the supernatant for inspection;

[0114] (4) Sample testing

[0115] The prepared supernatant and whole liquid samples were mixed with lipase for 15 minutes, and then the emulsion was added. The OD value of the emulsion was measured within a certain period of time. The inhibitory effect of the sample on the enzyme was judged by the change value of the emulsion (OD difference). The specific grouping is as follows:

[0116] Blank sample negative control group: 180 μL of 200-fold diluted emulsion + 10 μL of pH=8.0 tris-HCl buffer + 10 μL of MRS finished culture medium.

[0117] Sample test group 1: 180 μL of 200-fold diluted emulsion + 10 μL of 1% lipase solution + 10 μL of sample supernatant. Sample test group 2: 180 μL of 200-fold diluted emulsion + 10 μL of 1% lipase solution + 10 μL of sample whole solution. (5) Calculation formula for sample inhibition rate on enzyme

[0118] Sample hydrolysis rate% = (blank sample negative control group OD-supernatant or whole liquid test group OD) / blank sample negative control group OD*100%

[0119] Lipase hydrolysis rate % = (blank control group OD-enzyme solution negative control group OD) / blank control group OD * 100%

[0120] Sample inhibition rate % = (lipase hydrolysis rate - sample hydrolysis rate) / lipase hydrolysis rate * 100%

[0121] (6) Screening results

[0122] The experimental results are shown in Tables 2 and 3. This screening model was used to screen the lipase inhibition ability of a total of 148 strains of different species, and 5 strains with lipase inhibition activity were screened, among which Lactobacillus rhamnosus A36 had the best inhibitory effect on lipase. For specific data, see Table 2. The in vitro lipase inhibition ability of this strain is equivalent to orlistat at a concentration of 5 to 8 μg / mL. That is, this strain has the ability to produce lipase inhibitors, can inhibit the activity of lipase, and can be used to prepare weight loss drugs, health foods and other products.

[0123] Table 2 Lipase inhibitor screening results

[0124]

[0125] Table 3 Lipase inhibition ability of active strains

[0126]

[0127] 2.6 Strain identification

[0128] The rhamnosus lactobacillus A36 obtained by screening in part 2.5 was sequenced, and the molecular biological identification 16S rRNA sequence of the strain was compared with the homology of the strain in GenBank. It was identified as rhamnosus lactobacillus and named rhamnosus lactobacillus VB336. It was deposited in the China Center for Type Culture Collection on March 8, 2024, with the deposit address at Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the deposit number is CCTCC M 2024432. The scanning electron microscopy of rhamnosus lactobacillus VB336 is as follows Figure 1 The 16S rRNA sequence is shown in SEQ ID NO: 1:

[0129]

[0130] Example 3 Physiological and biochemical characteristics of Lactobacillus rhamnosus VB336 strain

[0131] The culture medium required for detecting the physiological and biochemical characteristics of Lactobacillus rhamnosus VB336, namely, MRS agar medium, was prepared as follows: peptone 10.0 g / L, beef extract powder 8.0 g / L, yeast extract powder 4.0 g / L, glucose 20.0 g / L, dipotassium hydrogen phosphate 2.0 g / L, diammonium hydrogen citrate 2.0 g / L, sodium acetate 5.0 g / L, magnesium sulfate 0.2 g / L, manganese sulfate 0.04 g / L, agar 20 g / L, Tween 80 1.0 g / L, pH = 6.7, and autoclaved at 121°C for 15 min.

[0132] The physiological and biochemical characteristics of the strain were analyzed according to the Bergey's Bacterial Identification Manual. The specific test contents are as follows:

[0133] (1) Contact enzyme: Take a small loop of Lactobacillus rhamnosus VB336 cultured at 37°C under anaerobic conditions for 24 h with a sterile inoculation loop and smear it on a glass slide with 3% hydrogen peroxide. Observe immediately. If bubbles are produced, it is positive; if no bubbles are produced, it is negative.

[0134] (2) Oxidase: Soak the oxidase test paper with distilled water, pick up a single Lactobacillus rhamnosus VB336 colony with a thin glass rod, and apply it to the test paper. If it turns blue or blue-purple within 30 seconds, it is a strong positive; if it does not change color within 2 minutes, it is a negative.

[0135] (3) Milk decomposition: Take a test tube containing 2 mL of sterile water, pick 1 to 3 colonies of Lactobacillus rhamnosus VB336 from the plate with an inoculating needle, grind carefully in sterile water to make a bacterial suspension, and add 100 μL of the bacterial suspension to the milk tube. Incubate at 37℃ for 24 to 48 hours. Observe after the incubation. If the layers turn pink and coagulate, it is positive; if there is no color change, it is negative.

[0136] (4) Hydrolysis of hippuric acid: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 4 h. After the incubation, slowly add 0.2 mL of ninhydrin solution along the wall of the test tube without shaking. Place at 37°C for 10 min and observe. If dark purple appears, it is positive; if light purple appears or there is no color change, it is negative.

[0137] (5) Indole test: Add 100 μL of the bacterial suspension in step (3) to peptone water, incubate at 37°C for 24 h, and then add 0.2 mL to 0.3 mL of Kovacs indole reagent. If red appears on the upper layer, it is a positive indole reaction; otherwise, it is a negative reaction.

[0138] (6) Urease: Add 100 μL of the bacterial suspension in step (3) into the biochemical tube and incubate at 37°C for 24 h. If a rose-red color appears on the upper layer, it is positive; otherwise, it is negative.

[0139] (7) Hydrogen sulfide production: Add 100 μL of the bacterial suspension in step (3) into the biochemical tube and incubate at 37°C for 18-24 hours. If a black color appears, it is positive; otherwise, it is negative.

[0140] (8) Glucose semisolid: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 18-24 hours. If yellow appears, it is positive; if gray-purple, purple or purple-red appears, it is negative.

[0141] (9) Arginine dihydrolase: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and culture at 37°C for 18 to 24 h. After inoculation, add sterile liquid paraffin to cover the surface of the culture medium. If purple or purple-red appears, it is positive; if yellow appears, it is negative.

[0142] (10) Amygdalin / rhamnose: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 18 to 24 h. If a yellow color appears, it is positive; if a light red or red color appears, it is negative.

[0143] (11) Glucose / xylose / melibiose / turanose / trehalose / galactose / arabinose / sorbitol: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 18 to 24 h. If a yellow color appears, it is positive; if a blue or blue-green color appears, it is negative.

[0144] (12) D-ribose / melezitose / mannose / fructose: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 24 to 48 h. If a yellow color appears, it is positive; if a gray-purple, purple or purple-red color appears, it is negative.

[0145] (13) Cellobiose / maltose / mannitol / salicylic acid / sucrose / raffinose / inulin / lactose: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 24 to 48 hours. If yellow appears, it is positive; purple or purple-gray is negative.

[0146] (14) Nitrate reduction: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 18 to 24 hours. After the incubation, add 2 to 3 drops of nitrate reduction reagent A and B respectively and observe immediately. If it turns red, it is positive; if it does not change color, it is negative.

[0147] (15) Gluconate: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 24 to 48 hours. After the incubation, add Benedict's reagent in a volume ratio of 1:1, mix well, boil for 10 minutes, and observe the results after cooling. If a yellow, orange or orange-red precipitate appears, it is positive; if a blue or green precipitate appears, it is negative.

[0148] (16) VP assay: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 2 to 4 days. Add the VP kit and shake the tube thoroughly to observe the results. A positive reaction will result in red color immediately or within a few minutes. If negative, continue incubation at 37°C for 4 hours and then observe again.

[0149] (17) Methyl red (MR): Add 100 μL of the bacterial suspension in step (3) to a biochemical tube, incubate at 37°C for 2-4 days, add one drop of methyl red reagent, and observe immediately. If bright red appears, it is positive; if yellow appears, it is negative.

[0150] (18) Gelatin liquefaction: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 24 to 72 hours. After taking out, place in a refrigerator at 2 to 8°C for 30 minutes and observe. If it is still liquid, the test result is positive, otherwise it is negative.

[0151] (19) Starch hydrolysis: Add 100 μL of the bacterial suspension in step (3) to the biochemical tube and incubate at 37°C for 48 to 96 hours. After the incubation, add iodine solution. If it does not turn blue, it is positive; if it turns blue, it is negative.

[0152] (20) Esculin: Add 100 μL of the bacterial suspension in step (3) into a biochemical tube and culture at 37°C for 24 to 48 h. After inoculation, add sterile liquid paraffin to cover the surface of the culture medium. If black appears, it is positive, and purple or purple-gray is negative.

[0153] The physiological and biochemical test results of the strain are shown in Table 4.

[0154] Table 4. Results of physiological and biochemical experiments on Lactobacillus rhamnosus VB336

[0155]

[0156] Note: + means positive; - means negative.

[0157] Example 4 Stability of Lactobacillus rhamnosus VB336 strain

[0158] 4.1 Experimental material preparation

[0159] (1) Preparation of culture medium

[0160] MRS medium: MRS broth 5.4% + 1.8% agar, pH = 6.5

[0161] (2) Preparation of simulated gastric fluid: physiological saline (sodium chloride: 0.9%), first prepare a 1% sodium chloride solution, adjust the pH to different levels and package, sterilize at 121°C for 30 min, pepsin 0.3% (prepare 3% concentration, filter with sterile membrane), mix at a ratio of 3% pepsin: 1% physiological saline = 1:9.

[0162] (3) Preparation of choline solution: Normal saline (sodium chloride: 0.9%) is first prepared into a 1% sodium chloride solution, and bovine choline is added at concentrations of 0%, 0.033%, 0.066%, 0.11%, 0.22%, and 0.33%, respectively. Sterilize at 121°C for 30 min. Add 0.1% trypsin (prepare 1% concentration and filter with a sterile membrane) at a ratio of 1% trypsin: 1% normal saline of each choline concentration = 1:9, and mix well.

[0163] (4) Preparation of intestinal fluid: Artificial simulated intestinal fluid was prepared according to the product instructions.

[0164] 4.2 Experimental methods

[0165] Take the frozen tube of Lactobacillus rhamnosus VB336 strain, apply the stock solution to the blank plate, and culture it in an anaerobically incubator at 37℃ for 1 day according to the growth characteristics. Scrape the bacterial moss and make a 20% glycerol tube to store at -80℃ for later use. At the same time, dilute and count the viable bacteria. 9 -10 10 CFU / mL is appropriate.

[0166] Take the counted bacterial suspension, thaw it and add it to the above-mentioned simulated choline solutions, gastric juice and intestinal juice. The amount of addition is: 10 μL bacterial suspension + 990 μL simulated liquid. After mixing, count the number of live bacteria in the 0h group at time 0, put the bacterial suspensions of the 2h group and the 4h group into anaerobic bags, place them in a 37°C incubator for culture, and take them out after culturing for 2h and 4h to count the number of live bacteria.

[0167] Table 5. Experimental materials

[0168]

[0169] like Figure 2 As shown in the figure, the survival rate of Lactobacillus rhamnosus VB336 in 0.03%-0.3% choline solution within 4 hours is as high as over 95%, indicating that Lactobacillus rhamnosus VB336 can stably exist in pancreatic juice, that is, the strain can adapt to the intestinal environment. Figure 3As shown in the figure, Lactobacillus rhamnosus VB336 died immediately in gastric juice at pH=1 and pH=2, 100% of the mortality rate in gastric juice at pH=3 within 2 hours, more than 80% of the mortality rate in gastric juice at pH=4 within 2 hours, and about 99% of the mortality rate within 4 hours. Therefore, in the subsequent formulation development process, the instability of Lactobacillus rhamnosus VB336 in gastric juice needs to be considered. Figure 4 As shown, after Lactobacillus rhamnosus VB336 was treated in the intestinal fluid at pH 8.0 for 4 h, the survival rate was 100%, that is, the strain could exist stably in the intestinal fluid.

[0170] Example 5 Antibacterial properties of Lactobacillus rhamnosus VB336 strain

[0171] (1) Prepare the culture medium of Lactobacillus rhamnosus VB336 as MRS agar medium:

[0172] Peptone 10.0g / L, beef extract powder 8.0g / L, yeast extract powder 4.0g / L, glucose 20.0g / L, dipotassium hydrogen phosphate 2.0g / L, diammonium hydrogen citrate 2.0g / L, sodium acetate 5.0g / L, magnesium sulfate 0.2g / L, manganese sulfate 0.04g / L, agar 20g / L, Tween 80 1.0g / L, pH 6.7, autoclave at 121℃ for 15min. The culture conditions are anaerobic culture at 37℃ for 1 day.

[0173] (2) Antibacterial model

[0174] The antibacterial experiment used a double-layer plate culture method:

[0175] Preparation of the lower experimental bacterial layer: After thawing the activated Lactobacillus rhamnosus VB336 cryovial, take 2 μL (the amount of live bacteria is 10 6 ) were spotted on MRS solid plates, with two spots for each strain, and the culture conditions were anaerobic overnight culture at 37°C.

[0176] Preparation of the upper pathogenic bacteria layer: The upper culture medium after high temperature sterilization is cooled to 40-50°C, and different pathogens are added as required. The final concentration of pathogens is 10 8 / mL, add 7 mL of culture medium containing pathogenic bacteria to the above-mentioned grown Lactobacillus rhamnosus VB336 plate. After the plate solidifies, culture it under appropriate culture conditions according to the growth conditions of different pathogens. After the upper plate grows well, observe whether an inhibition zone is formed around the Lactobacillus rhamnosus VB336 colony, and measure the size of the inhibition zone to determine the antibacterial ability of Lactobacillus rhamnosus VB336.

[0177] The results are shown in Table 6. Lactobacillus VB336 has a good inhibitory effect on 11 pathogenic bacteria. Among them, Escherichia coli, Staphylococcus aureus, Salmonella, Listeria, Shigella, Enterococcus faecalis, and Clostridium perfringens are all intestinal pathogens; Malassezia is a skin pathogen; Candida albicans is a vaginal pathogen; Porphyromonas gingivalis and Streptococcus mutans are oral pathogens.

[0178] Table 6. Antibacterial ability of Lactobacillus rhamnosus VB336

[0179]

[0180] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "embodiment" or "specific embodiment" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment are included in at least one embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments and features of the different embodiments described in this specification without contradiction.

[0181] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) VB336, characterized in that The Lactobacillus rhamnosus VB336 was deposited in the China Center for Type Culture Collection on March 8, 2024, with the deposit number being CCTCC M2024432.

2. A fermentation broth, characterized in that: The fermentation broth is obtained by fermenting the Lactobacillus rhamnosus VB336 according to claim 1, and the fermentation broth contains the Lactobacillus rhamnosus VB336 according to claim 1.

3. A bacterial suspension, characterized in that: The bacterial suspension comprises the Lactobacillus rhamnosus VB336 according to claim 1.

4. Use of the Lactobacillus rhamnosus VB336 according to claim 1, the fermentation liquid according to claim 2 or the bacterial suspension according to claim 3 in the preparation of weight loss medicines, health products or feeds that inhibit lipase activity.

5. Use of the Lactobacillus rhamnosus VB336 according to claim 1, the fermentation liquid according to claim 2 or the bacterial suspension according to claim 3 in the preparation of medicines or feeds for inhibiting the activity of pathogenic bacteria, wherein the pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Listeria, Shigella, Enterococcus faecalis, Clostridium perfringens, Malassezia, Candida albicans, Porphyromonas gingivalis and Streptococcus mutans.

6. A composition, characterized in that The composition comprises at least one of the Lactobacillus rhamnosus VB336 according to claim 1, the fermentation broth according to claim 2, and the bacterial suspension according to claim 3.

7. The composition according to claim 6, characterized in that The dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

8. The composition according to claim 6, characterized in that The composition also includes an excipient.

9. The composition according to claim 6, characterized in that The composition also includes a carrier.

10. The composition according to claim 8, characterized in that The excipients include at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler and a sustained-release agent.

11. The composition according to claim 9, characterized in that The carrier comprises at least one selected from sugars, calcium phosphates, stearic acid alkaline earth metal salts, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

12. A method for inhibiting lipase activity in vitro, characterized in that: include: At least one of the Lactobacillus rhamnosus VB336 according to claim 1, the fermentation liquid according to claim 2, and the bacterial suspension according to claim 3 is mixed with the lipase.

13. A method for inhibiting the growth of pathogenic bacteria in vitro, characterized in that: include: At least one of the Lactobacillus rhamnosus VB336 described in claim 1, the fermentation broth described in claim 2, and the bacterial suspension described in claim 3 is co-cultured with pathogenic bacteria, wherein the pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Listeria, Shigella, Enterococcus faecalis, Clostridium perfringens, Malassezia, Candida albicans, Porphyromonas gingivalis, and Streptococcus mutans.